Medindia

X

Acorda's Ampyra is Seen as a Welcomed Addition to Existing Disease-Modifying Agents for the Improvement of Walking Speed in Multiple Sclerosis Patients, According to U.S. Neurologists, Even as Product Access Proves Frustrating

Wednesday, June 2, 2010 General News J E 4
Advertisement

BioTrends Research Group, Inc.

Decision Resources, Inc.

Sharon Funk

Christopher Comfort

404-223-2963

781-296-2597

sfunk@bio-trends.com  

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
CSL Behring Receives Canadian Notice of Compliance...
S
For the Treatment of HIV, Three Novel Products Fro...